EBElena Bogoslovskaya

Elena Bogoslovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Bogoslovskaya has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Denis O. Omelchenko

    Laboratory of Plant Genomics, Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia

    1 shared publication
  • Dina Glazkova

    Department of Molecular Diagnostic and Epidemiology, Federal Budget Institution of Science “Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance, 111123 Moscow, Russia

    1 shared publication
  • Felix Anatolevich Urusov

    Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia

    1 shared publication
  • Galina M. Tsyganova

    Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia

    1 shared publication
  • German A. Shipulin

    Centre for Strategic Planning and Management of Biomedical Health Risks

    1 shared publication
  • Katerina Kersting

    Department of Molecular Diagnostic and Epidemiology, Federal Budget Institution of Science “Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance, 111123 Moscow, Russia

    1 shared publication

Latest Publications

  • Open Access

    Optimization of Polycistronic Anti-CCR5 Artificial microRNA Leads to Improved Accuracy of Its Lentiviral Vector Transfer and More Potent Inhibition of HIV-1 in CD4+ T-Cells

    by Felix Urusov, Dina Glazkova, Denis Omelchenko, Elena Bogoslovskaya, Galina Tsyganova, Katerina Kersting, German Shipulin, Vadim Pokrovsky

    C-C chemokine receptor type 5 (CCR5) is utilized by human immunodeficiency virus (HIV) as a co-receptor for cell entry. Suppression of the CCR5 gene by artificial microRNAs (amiRNAs) could confer cell resistance. In previous work, we created a lentivector that encoded the polycistron of two identical amiRNAs that could effectively suppress CCR5. However, tandem repeats in lentiviral vectors led to deletions of the repeated sequences during reverse transcription of the vector RNA. To solve this problem, we have created a new amiRNA against CCR5, mic1002, which has a different microRNA scaffold and targets a different sequence. Replacing one of the two identical tandem amiRNAs in the polycistron with the mic1002 amiRNA increased the accuracy of its lentiviral vector transfer while retaining its ability to effectively suppress CCR5. A lentiviral vector containing two heterogenic amiRNAs significantly inhibited HIV replication in a vector-transduced human CD4+ lymphocyte culture.